DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Nilotinib
Nilotinib
Management of Chronic Myelogenous Leukemia in Pregnancy
Nilotinib (Tasigna®) EOCCO POLICY
Tasigna, INN-Nilotinib
The Effects of Combination Treatments on Drug Resistance in Chronic Myeloid Leukaemia: an Evaluation of the Tyrosine Kinase Inhibitors Axitinib and Asciminib H
Bridging from Preclinical to Clinical Studies for Tyrosine Kinase Inhibitors Based on Pharmacokinetics/Pharmacodynamics and Toxicokinetics/Toxicodynamics
Download
Thyrosin Kinase Inhibitors: Nilotinib F
Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
Effects of Tyrosine Kinase Inhibitors (Nilotinib) on Male Mice Infertility
Sorafenib Inhibits the Imatinib-Resistant KIT Gatekeeper
Your Pharmacy Benefits Welcome to Your Pharmacy Plan
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition Richard D
Effects of Imatinib, Nilotinib, Dasatinib on VEGF and VEGFR-1 Levels in Patients with Chronic Myelogenous Leukemia
(Ara-C) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Overexpression
Phase II Trial of Nilotinib in Patients with Metastatic Malignant Melanoma Harboring KIT Gene Aberration: a Multicenter Trial of Korean Cancer Study Group (UN10-06)
Clinical Pharmacology and Biopharmaceutics Review(S)
For Health Professionals Who Care for Cancer Patients
Recent Advances That Are Redefining Oncology
Top View
Kinase Drug Discovery 20 Years After Imatinib: Progress and Future Directions
Novel TKI-Resistant BCR-ABL1 Gatekeeper Residue Mutations Retain in Vitro Sensitivity to Axitinib
Nilotinib Vs Imatinib in Patients with Newly Diagnosed
Axitinib and Sorafenib Are Potent in Tyrosine Kinase Inhibitor Resistant
2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
Resistance to C-KIT Kinase Inhibitors Conferred by V654A Mutation
Bladder Cancer
Intolerant Patients with Chronic Myeloid Leukemia in Blastic Phase
Nintedanib: Drug Information
Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: a Focus on Transporters and Lysosomal Sequestration
Tasigna® (Nilotinib)
Negative HNSCC – Alteration of EGFR and VEGFR-2 Expression in Vitro
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Therapeutic Drug Monitoring of 9 New Anticancer Agents by High-Performance Liquid Chromatography-Tandem Mass Spectrometry V
Oncology Medications Policy (1403)
Management of Cardiac Toxicity Induced by Chemotherapy
Tasigna (Nilotinib) Capsules Label
Oncology Therapy for the Generalist
Nilotinib Shows Prolonged Intracellular Accumulation Upon Pulse-Exposure: a Novel Mechanism for Induction of Apoptosis in CML Cells
Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
List of Cleared Or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
Oncology Center of Excellence 2019 Annual Report
Limited Clinical Activity of Nilotinib and Sorafenib in FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukemia with Imatinib-Resistant T674I Mutation
Therapeutic Drug Monitoring and Tyrosine Kinase Inhibitors (Review)
Pharmacological Targeting of the KIT Growth Factor Receptor: a Therapeutic Consideration for Mast Cell Disorders
203341Orig1s000
Ninetedanib (OFEV) National Drug Monograph March 2015
TASIGNA Safely and Effectively
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Oral Targeted Therapy for Cancer
BCBSNM Drug List Limitations, Exclusions, and Preauthorization Criteria
Second Generation Tyrosine Kinase Inhibitors for the Treatment of Chronic Myelogenous Leukaemia with Intolerance of Hematologic Resistance to Imatinib
Generic (Brand) Name Mechanism of Action Mechanism of Action
Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: an Analysis of the FDA Adverse Event Reporting System Database (FAERS)
Emtansine (T-DM1) Resistance in HER2-Positive Cancer
Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: a Perspective
In the Treatment of Early Diffuse Systemic Sclerosis: an Open-Label, Pilot Clinical Trial Jessica K
The Use of the Tyrosine Kinase Inhibitor
Development of Pigmentation-Regulating Agents by Drug Repositioning
Surgical Resection of Recurrent Gastrointestinal Stromal Tumor After
Antimalarial Activity of Kinase Inhibitor, Nilotinib, in Vitro and in Vivo
UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation
Living Well with Chronic Myeloid Leukaemia (CML)
Safe Handling of Oral Antineoplastic Medications: Focus on Targeted Therapeutics in the Home Setting
A New Therapeutic Option for Advanced Gastrointestinal Stromal Tumors
Publication Agenda CHMP 07-10 December 2020
Blue Cross and Blue Shield of Texas July 2017 Basic Drug List I
Alternating Or Combined Therapy with Axitinib and Bosutinib for Patients with Chronic Myeloid Leukemia in Chronic, Accelerated Or Blastic Phases 2015-0787
The Efficacy of Lapatinib and Nilotinib in Combination with Radiation Therapy in a Model of NF2 Associated Peripheral Schwannoma
Extracellular Domain C-Kit Mutation with Duplication of Ser501ala502
Thyroid Effects of Tyrosine Kinase Inhibitors
Label Multicenter Clinical Trial, a Total of 438 Patients Were Treated (CML-CP=318; CML-AP=120)
Sorafenib and Nilotinib Resensitize Tamoxifen Resistant Breast Cancer Cells to Tamoxifen Treatment Via Estrogen Receptor Α
SAFE PRACTICES in ORAL CHEMOTHERAPY: I Have No Conflicts of Interest to Disclose Related to the the Pharmacist’S Role in the Outpatient Content of This Program